N-acetylglutamate Synthase: Structure, Function & Defects

N-乙酰谷氨酸合成酶:结构、功能

基本信息

  • 批准号:
    8035600
  • 负责人:
  • 金额:
    $ 9.98万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-04-01 至 2012-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): N-acetylglutamate synthase (NAGS) is an enzyme that produces the cognate cofactor N-acetylglutamate (NAG), an essential allosteric activator of the first and rate limiting enzyme of ureagenesis (CPS I) in mammals, and the first committed substrate for arginine biosynthesis in microorganisms. Our cloning and expression of the mouse and human NAGS genes and many other NAGS genes from various species, makes it now possible to gain structure/function insights into this interesting protein. We found in a number of proteobacteria species (X. campestris, M. maris, O. alexandrii, X. axonopodis, and X. fastidiosa Dixon) a gene for a bifunctional NAGS/NAGK that is similar to mammalian NAGS and for which we have obtained protein crystals. Recently, we obtained a high quality density map which will lead to the determination of the first three-dimensional structure of NAGS (from N. gonorrhoeae). Since NAGS is a likely regulator of ureagenesis and its function is allosterically affected by arginine, it is now possible to understand the mechanism(s) of the arginine effect and to compare the regulation of NAGS in hepatic vs. intestinal, tissues. The deficiency of NAG in inherited NAGS deficiency, organic acidemias and valproate treatment causes hyperammonemia that frequently leads to brain damage, developmental disabilities and death. Better understanding of the NAG/NAGS system will improve the diagnosis and treatment of these conditions. The specific aims of this project are 1) To solve the liganded and unliganded structures of NAGS and characterize mechanisms for catalysis and the effect of arginine; 2) To characterize the biochemical properties of NAGS proteins across phyla, focusing on the effect of arginine on structure and function; 3) To differentiate regulatory mechanisms that are specific to liver ureagenesis by characterizing and comparing the regulation of NAGS expression in liver and intestine; 4) To determine the functional effects of naturally-occurring mutations that cause inherited NAGS deficiency. Biochemical, crystallographic and molecular methods will be employed to gain an in depth understanding of the structural biology, biochemistry, pathophysiology, genotype/phenotype correlations of the NAGS genes and proteins in the context of evolutionary development of this system. After the first three- dimensional structure of NAGS has been solved, other structures of refractory NAGS proteins will become available. This will lead to constructing a structural model of mammalian NAGS, deriving at a catalytic mechanism, determining the mechanism of arginine effect, and the effects of mutations causing NAGS dysfunction and hyperammonemia.
描述(由申请人提供): N-乙酰谷氨酸合酶(NAGS)是产生同源辅因子N-乙酰谷氨酸(NAG)的酶,其是哺乳动物中第一和限速尿素生成酶(CPS I)的必需变构激活剂,并且是微生物中精氨酸生物合成的第一个确定底物。我们对小鼠和人类NAGS基因以及来自不同物种的许多其他NAGS基因的克隆和表达,使我们现在有可能深入了解这种有趣的蛋白质的结构/功能。我们发现在一些变形菌物种(X。campestris,M. maris、马里斯岛O. alexamii,黄毛菊X. axonopodis和X. fastidiosa狄克逊)的双功能NAGS/NAGK的基因,其类似于哺乳动物NAGS,并且我们已经获得了其蛋白质晶体。最近,我们获得了一个高质量的密度图,这将导致确定的第一个三维结构的NAGS(从N。淋病)。由于NAGS可能是尿素生成的调节剂,并且其功能受精氨酸的变构影响,因此现在可以了解精氨酸作用的机制并比较肝脏与肠道组织中NAGS的调节。遗传性NAGS缺乏、有机酸缺乏和丙戊酸盐治疗中NAG缺乏导致高氨血症,高氨血症经常导致脑损伤、发育障碍和死亡。更好地了解NAG/NAGS系统将改善这些疾病的诊断和治疗。本项目的具体目标是:1)解决NAGS的配体和非配体结构,并表征其催化机制和精氨酸的作用:2)表征跨门NAGS蛋白的生化性质,重点是精氨酸对结构和功能的影响;第三章通过表征和比较NAGS在肝脏中表达的调节,肠; 4)确定导致遗传性NAGS缺陷的自然发生的突变的功能效应。生物化学,晶体学和分子生物学的方法将被用来深入了解结构生物学,生物化学,病理生理学,基因型/表型相关的NAGS基因和蛋白质在这个系统的进化发展的背景下。在解决了NAGS的第一个三维结构之后,难治性NAGS蛋白的其他结构将变得可用。这将导致构建哺乳动物NAGS的结构模型,推导出在催化机制,确定精氨酸作用的机制,以及突变引起NAGS功能障碍和高氨血症的影响。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mendel Tuchman其他文献

Mendel Tuchman的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mendel Tuchman', 18)}}的其他基金

Overall Adminstration of Rare Diseases Clinical Research Consortia (RDCRC)
罕见病临床研究联盟(RDCRC)的总体管理
  • 批准号:
    8916167
  • 财政年份:
    2015
  • 资助金额:
    $ 9.98万
  • 项目类别:
Pilot/Demonstration Clinical Research Projects Program
试点/示范临床研究项目计划
  • 批准号:
    8916164
  • 财政年份:
    2015
  • 资助金额:
    $ 9.98万
  • 项目类别:
N-carbamylglutamate in the treatment of hyperammonemia
N-氨甲酰谷氨酸治疗高氨血症
  • 批准号:
    8061384
  • 财政年份:
    2010
  • 资助金额:
    $ 9.98万
  • 项目类别:
N-CARBAMYLGLUTAMATE (CARBAGLU) IN THE TREATMENT OF HYPERAMMONEMIA
N-氨甲酰谷氨酸(CARBAGLU)治疗高氨血症
  • 批准号:
    8167358
  • 财政年份:
    2010
  • 资助金额:
    $ 9.98万
  • 项目类别:
N-carbamylglutamate in the treatment of hyperammonemia
N-氨甲酰谷氨酸治疗高氨血症
  • 批准号:
    7848468
  • 财政年份:
    2009
  • 资助金额:
    $ 9.98万
  • 项目类别:
N-acetylglutamate Synthase: Structure, Function & Defects
N-乙酰谷氨酸合成酶:结构、功能
  • 批准号:
    7809804
  • 财政年份:
    2009
  • 资助金额:
    $ 9.98万
  • 项目类别:
N-carbamylglutamate in the treatment of hyperammonemia
N-氨甲酰谷氨酸治疗高氨血症
  • 批准号:
    7505006
  • 财政年份:
    2008
  • 资助金额:
    $ 9.98万
  • 项目类别:
N-carbamylglutamate in the treatment of hyperammonemia
N-氨甲酰谷氨酸治疗高氨血症
  • 批准号:
    8254226
  • 财政年份:
    2008
  • 资助金额:
    $ 9.98万
  • 项目类别:
N-carbamylglutamate in the treatment of hyperammonemia
N-氨甲酰谷氨酸治疗高氨血症
  • 批准号:
    7667880
  • 财政年份:
    2008
  • 资助金额:
    $ 9.98万
  • 项目类别:
N-carbamylglutamate in the treatment of hyperammonemia
N-氨甲酰谷氨酸治疗高氨血症
  • 批准号:
    9036417
  • 财政年份:
    2008
  • 资助金额:
    $ 9.98万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 9.98万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 9.98万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 9.98万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 9.98万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 9.98万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 9.98万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 9.98万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 9.98万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 9.98万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 9.98万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了